Multiple Myeloma Clinical Trial
Official title:
Correlation Between the Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple Myeloma.
The measurement of 24-hour proteinuria allows an assessment of treatment response in patients
with multiple myeloma. But it is difficult and restrictive to make.
This study was therefore designed to investigate the correlation between the ratio of
proteinuria / creatinine on samples, easier to obtain, and the 24-hour proteinuria in
assessing response to this treatment .
The measure of 24-hour proteinuria is an important biomarker for multiple myeloma.
Multiple myeloma is often accompanied by proteinuria overhead of secretion by plasma cells of
large quantities of immunoglobulin free light chains (FLC) kappa or lambda. This proteinuria
is composed of monoclonal FLC. The measure of the urinary concentration of FLC is an
important biomarker for both diagnosis and evaluation of response to treatment of light chain
multiple myeloma but also in intact immunoglobulins multiple myeloma.
The 24-hour proteinuria coupled with urine protein electrophoresis is the standard method for
measuring the concentration of urinary FLC. However, it is difficult to obtain a reliable
collection of the urine of 24 hours which can make it difficult to assess response to therapy
in some patients. It would be interesting to assess proteinuria in a single urine sample
collected at any time of day.
Contribution of urinary protein/creatinine ratio for assessment of proteinuria of glomerular
origine.
For reasons of convenience, the extent of 24-hour proteinuria was increasingly abandoned by
nephrologists in favor of urinary protein/creatinine ratio (UPCR). The use of UPCR measured
on a sample of urine overcomes the inaccuracies related to the collection of 24 or variations
in urine concentration. This report has been validated against the 24-hour proteinuria for
screening or monitoring of renal glomerular diseases by the French Society of Nephrology. In
theory, the UPCR is measured on a urine sample, taken preferably in the morning. In practice,
the precision of a measurement at any time of day is quite acceptable.
Using the urinary protein/creatinine ratio for assessment of response in multiple myeloma?
The use of UPCR has been validated in patients with renal glomerular disease and especially
in diabetic nephropathy. However, the UPCR has not been validated for the assessment of
proteinuria overload such as those seen in myeloma. Two recent papers have studied the UPCR
in multiple myeloma. The results of these articles suggest:
- That the UPCR is well correlated with the 24-hour proteinuria
- The UPCR varies over time depending on the response to treatment and could therefore be
used to monitor patients on treatment
However, given their limits, these two articles do not alow to recommend the widespread use
of UPCR instead of the classic 24-hour proteinuria in clinical practice yet. Prospective
studies are needed to analyze the correlation between UPCR and proteinuria of 24 hours to
assess response to therapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |